Company Filing History:
Years Active: 2018-2019
Title: Hideo Kanehiro: Innovator in Pharmaceutical Treatments
Introduction
Hideo Kanehiro is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of liver disorders. With a total of 2 patents, Kanehiro's work focuses on innovative methods for addressing non-alcoholic steatohepatitis.
Latest Patents
Kanehiro's latest patents include compositions and methods for treating non-alcoholic steatohepatitis. The first patent discloses a method for treating a fatty liver disorder in a subject in need thereof. This involves selecting a subject who is non-diabetic, pre-diabetic, mildly diabetic, or has normal biliary tract function. The treatment consists of administering a therapeutically effective amount of a pharmaceutical composition that includes ethyl eicosapentanoate (EPA-E). In some cases, the EPA-E present may be at least 40% by weight of the total fatty acids and their derivatives. The second patent also addresses the treatment of fatty liver disease, focusing on subjects with similar conditions and administering a composition comprising EPAs.
Career Highlights
Kanehiro is associated with Mochida Pharmaceutical Co., Ltd., where he has been instrumental in developing innovative treatments. His work has garnered attention for its potential to improve the quality of life for individuals suffering from liver disorders.
Collaborations
Kanehiro has collaborated with notable colleagues, including Tsuyoshi Harada and Kiyoshi Mizuguchi. Their combined expertise has contributed to the advancement of research in the pharmaceutical field.
Conclusion
Hideo Kanehiro's contributions to the treatment of non-alcoholic steatohepatitis highlight his role as an innovator in the pharmaceutical industry. His patents reflect a commitment to improving health outcomes for patients with liver disorders.